A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
NCT04814615
Age 21 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and provide more effective options for managing the disease. Here are some key details about the study:
- The study investigates a unique combination of therapies that have not been widely used together before.
- It includes a specific treatment regimen that targets the disease in a novel way, potentially leading to better results.
- Patients will receive a tailored treatment plan based on their individual needs and responses to therapy.
- The study aims to assess the effectiveness of this combination in reducing symptoms and improving quality of life for patients.
- Researchers are also looking at how well patients tolerate the treatment and any side effects that may occur.
- This study is being conducted at multiple sites, allowing for a diverse group of participants and more comprehensive data collection.
- By focusing on a personalized approach, the study hopes to identify which patients may benefit the most from this treatment strategy.
Third Opinion AI Generated Synopsis
Trial Summary
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
